Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SN50 is a cell permeable NF-κB translocation inhibitor.
Description | SN50 is a cell permeable NF-κB translocation inhibitor. |
In vitro | Compared with vehicle-treated groups,pretreatment with SN50 results in a significant reduction in amount of PI-positive cells at 12, 24, and 48 h time-point post TBI [1]. Local SN50 inhibits the activation of nuclear factor-κB in local cells and reduces the occurrence of epithelial defects/ulcers during corneal healing. Myofibroblast generation, macrophage invasion, activity of matrix metalloproteinases, basement membrane destruction, and expression of cytokines are all decreased in treated corneas compared with controls[2]. Treating the human gastric cancer cells SGC7901 with SN50 could significantly enhance the effects of LY294002 on inducing cell death after 24 h[3]. SN50 can inhibit translocation of NF-kB and production of inflammatory cytokines that are implicated in lipopolysaccharide (LPS)-induced lung injury[4]. |
In vivo | SN50 accelerates the recovery of motor functional outcome from 1st to 4th day. Animals subjected to SN50 pretreatment demonstrate a significant decrease in the visuospatial learning latencies relative to the control group at 7 and 8 days post-TBI. Pretreatment with SN50 results in a significant reduction of NF-κB p65 protein levels from 6 to 48 h post-TBI and TNF-a protein levels from 12 to 48 h post-TBI[1]. |
Molecular Weight | 2781.5 |
Formula | C129H230N36O29S |
CAS No. | 213546-53-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (17.98 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SN50 213546-53-3 NF-Κb NF-κB SN-50 SN 50 inhibitor inhibit